Last reviewed · How we verify
TOBI® PODHALER®
At a glance
| Generic name | TOBI® PODHALER® |
|---|---|
| Sponsor | Mylan Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
- Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules (PHASE4)
- Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients (PHASE3)
- Pharmacokinetic and Pharmacoscintigraphic Comparison of TobrAir® 6.0 With TOBI® and TOBI® Podhaler™ (PHASE1)
- Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI) (PHASE4)
- Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |